BIOXCEL THERAPEUTICS

BioXcel Therapeutics is a clinical-stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. Its drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. They believe that this differentiated approach has the po... tential to reduce the cost and time of drug development in diseases with substantial unmet medical needs. BXCL501 is a sublingual thin film formulation of the a2a adrenergic receptor agonist dexmedetomidine, or Dex, for acute treatment of agitation resulting from neurological and psychiatric disorders. It intends to utilize the 505(b)(2) pathway for BXCL501, initiated a Phase 1b safety study using the IV formulation of Dex in mild probable Alzheimer's Disease in December 2017, and plans to do the same for schizophrenia patients in the 1H18, with data expected in the 2H18. BXCL701 (formerly Talabostat) is an immuno-oncology agent for the treatment of a rare form of prostate cancer and pancreatic cancer.

#SimilarOrganizations #People #Financial #Event #Website #More

BIOXCEL THERAPEUTICS

Social Links:

Facebook

Twitter

Industry:

Artificial Intelligence Biopharma Biotechnology Health Care

Founded:

2017-01-01

Address:

Branford, Connecticut, United States

Country:

United States

Website Url:

http://www.bioxceltherapeutics.com

Total Employee:

101+

Status:

Active

Contact:

203 643 8060

Email Addresses:

[email protected]

Total Funding:

140 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins Microsoft Exchange Online

Similar Organizations

edgewise-therapeutics-logo

Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

Current Employees Featured

vincent-j-oneill_image

Vincent J. O&s;Neill
Vincent J. O'Neill CMO & SVP Clinical Development @ BioXcel Therapeutics
CMO & SVP Clinical Development
2017-07-01

vimal-mehta_image

Vimal Mehta
Vimal Mehta Co-Founder & Chief Executive Officer @ BioXcel Therapeutics
Co-Founder & Chief Executive Officer
2017-03-01

matt-wiley_image

Matt Wiley
Matt Wiley SVP, Chief Commercial Officer @ BioXcel Therapeutics
SVP, Chief Commercial Officer
2022-01-01

jeffrey-sabados_image

Jeffrey Sabados
Jeffrey Sabados Program Management Support and Government Relations @ BioXcel Therapeutics
Program Management Support and Government Relations
2019-01-01

Founder

vimal-mehta_image

Vimal Mehta

Stock Details

Company's stock symbol is FRA:BX2

Investors List

qatar-investment-authority_image

Key Employee Changes

Date	New article
2022-01-19	BioXcel Therapeutics Appoints Matt Wiley Chief Commercial Officer

Official Site Inspections

http://www.bioxceltherapeutics.com Semrush global rank: 2.05 M Semrush visits lastest month: 10.22 K

Host Informations
Whois Informations

Loading ...